Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 908 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Age - Related Macular Degeneration Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Goji vs. Fiber on Macular Degeneration

NCT06237127
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Goji berry, Fiber
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
65 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 15, 2026, 10:22 AM EDT
Completed No phase listed Observational

Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration

NCT01526070
View directory record Official record
Conditions
Exudative Age-related Macular Degeneration
Interventions
Intravitreal injection of Aflibercept
Drug
Lead sponsor
Stanford University
Other
Eligibility
50 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 15, 2026, 10:22 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

NCT03999801
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions
RGX-314
Genetic
Lead sponsor
AbbVie
Industry
Eligibility
50 Years and older
Enrollment
865 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
9
States / cities
Phoenix, Arizona • Santa Barbara, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Oct 15, 2026, 10:22 AM EDT
Active, not recruiting Phase 3 Interventional

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

NCT06668064
View directory record Official record
Conditions
Wet Age Related Macular Degeneration, wAMD
Interventions
EYP-1901, Aflibercept (2.0 mg)
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 15, 2026, 10:22 AM EDT
Not listed Phase 2Phase 3 Interventional

Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration

NCT02127463
View directory record Official record
Conditions
Non-Exudative Age Related Macular Degeneration
Interventions
MC-1101, MC-1101 Vehicle
Drug
Lead sponsor
MacuCLEAR, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Oct 15, 2026, 10:22 AM EDT
Terminated Not applicable Interventional

Tools to Optimize Patient Presentation After Onset of Exudative Age-Related Macular Degeneration (AMD)

NCT01337414
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
VMS diary booklet, Standard of Care
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 15, 2026, 10:22 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF Therapy

NCT00809419
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
NeoVista Ophthalmic System
Device
Lead sponsor
NeoVista
Industry
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Phoenix, Arizona • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jul 27, 2011 · Synced Oct 15, 2026, 10:22 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

High Resolution Retinal Imaging

NCT01866371
View directory record Official record
Conditions
Stargardts, Retinitis Pigmentosa, Age-related Macular Degeneration, Choroideremia, Geographic Atrophy
Interventions
Retinal imaging
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
7 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 15, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000

NCT00784225
View directory record Official record
Conditions
Cataract, Macular Degeneration
Interventions
selenium, vitamin E, vitamin E placebo, selenium placebo
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
50 Years to 120 Years · Male only
Enrollment
13,475 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 15, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

NCT02689518
View directory record Official record
Conditions
Macular Degeneration, Wet Macular Degeneration
Interventions
Intravitreal aflibercept injection
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 15, 2026, 10:22 AM EDT
Not listed No phase listed Observational

A Comparison of the Checkup Vision Assessment System to Standard Vision Assessment Tools

NCT02871817
View directory record Official record
Conditions
Age - Related Macular Degeneration, Diabetic Retinopathy, Metamorphopsia
Interventions
Paxos Checkup Study Mobile Medical Application
Other
Lead sponsor
Digisight Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Mountain View, California • Fort Myers, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Oct 15, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

NCT05381948
View directory record Official record
Conditions
Wet Age-related Macular Degeneration
Interventions
EYP-1901, Aflibercept 2mg/0.05mL Inj,Oph
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
67
States / cities
Phoenix, Arizona • Springdale, Arkansas • Beverly Hills, California + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 15, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery

NCT01284478
View directory record Official record
Conditions
Pseudophakic Cystoid Macular Edema,, Diabetic Macular Edema
Interventions
Dexamethasone Implant
Drug
Lead sponsor
Northern California Retina Vitreous Associates
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 15, 2026, 10:22 AM EDT
Recruiting Phase 3 Interventional

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

NCT06541704
View directory record Official record
Conditions
Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
Interventions
Pozelimab, Cemdisiran, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
158
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 10:22 AM EDT
Completed Phase 4 Interventional

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

NCT05626478
View directory record Official record
Conditions
Corneal Edema, Corneal Defect, Anterior Chamber Inflammation, Ocular Pain, Corneal Staining, Visual Outcome, CME - Cystoid Macular Edema
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 15, 2026, 10:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT07215234
View directory record Official record
Conditions
Geographic Atrophy
Interventions
SAR446597, Sham Comparator
Drug
Lead sponsor
Sanofi
Industry
Eligibility
60 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
28
States / cities
Peoria, Arizona • Scottsdale, Arizona • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 15, 2026, 10:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops

NCT00659555
View directory record Official record
Conditions
Macular Degeneration
Interventions
pazopanib eye drops, Ketoconozole tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 15, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT03739593
View directory record Official record
Conditions
Macular Edema
Interventions
AR-1105-CF1, AR-1105-CF2
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Phoenix, Arizona • Beverly Hills, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 15, 2026, 10:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

AREDS 2 Ancillary Spectral Domain Optical Coherence Tomography Study

NCT00734487
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
50 Years to 85 Years
Enrollment
470 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
4
States / cities
Atlanta, Georgia • Bethesda, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 15, 2026, 10:22 AM EDT
Completed Not applicable Interventional Results available

COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy

NCT05961332
View directory record Official record
Conditions
Macular Degeneration, Age Related, Geographic Atrophy
Interventions
Spectralis FAF imaging, Optos imaging, Zeiss Clarus 700 imaging
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 15, 2026, 10:22 AM EDT
Terminated No phase listed Observational

Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy

NCT02875704
View directory record Official record
Conditions
Stargardt Disease, Diabetic Retinopathy, Macular Degeneration (Age Related)
Interventions
Anterior Chamber (AC) Tap
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 15, 2026, 10:22 AM EDT
Completed Not applicable Interventional

Proton Radiation Therapy for Macular Degeneration

NCT01833325
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Proton radiation
Radiation
Lead sponsor
University of Florida
Other
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 15, 2026, 10:22 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Use of Self-management Group to Improve Quality of Life in Patients With Low Vision

NCT03046485
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Self management program 'Living with Vision Loss'
Behavioral
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
55 Years to 95 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 15, 2026, 10:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

NCT02686658
View directory record Official record
Conditions
Geographic Atrophy, Dry Age-Related Macular Degeneration
Interventions
Avacincaptad Pegol, Sham
Drug · Other
Lead sponsor
IVERIC bio, Inc.
Industry
Eligibility
50 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
55
States / cities
Phoenix, Arizona • Tucson, Arizona • Campbell, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 15, 2026, 10:22 AM EDT